The nanovesicles integrating a prodrug of oxaliplatin (OXA) can passively accumulate at the tumor site and penetrate deep into the tumor mass via matrix metalloproteinase 2‐mediated cleavage of the polyethylene glycol corona. Here, MMP2 is linked to neoplasm.